Guobio Pharmaceutical Invests in Puyen Biotechnology, Completing Dual Platform for Drugs and Delivery Devices

Guobio Pharmaceutical has solidified its strategic position in the healthcare industry by completing a significant investment in Puyen Biotechnology. The company announced it has acquired a 54% equity stake in Puyen, a developer of high-end medical devices, effectively establishing a dual platform focused on both drug formulation and precision drug delivery systems.

This integration is a key step in Guobio's long-term strategy, which centers on the "drug-device integration" concept. The company's existing products, such as L606 and L608, were developed with a combined approach of new formulations and advanced inhaler devices. The acquisition of Puyen Biotechnology is expected to enhance Guobio's research and development capabilities and bolster its potential for international collaborations.

Puyen Biotechnology brings substantial expertise in high-end medical device research and development, holding multiple patents for medical devices and operating under international GMP standards. Their core technologies in precision drug delivery, particularly for inhalation devices, include patented features for controlling drug release based on patient inhalation. These technologies are already integrated into the design of Guobio's L606 and L608 nebulizers.

With Puyen's products already holding CE Mark in Europe and TFDA approval in Taiwan, and with existing sales records, the company is also pursuing MDR certification in Europe. Guobio's chairman, Wang Jian-zhi, stated that the integration allows the group to independently develop drug-device combination products regardless of the administration route. This dual-platform structure aims to drive the development of competitive combination products and expand the business scope of Puyen's own devices, ultimately enhancing the group's overall value and advancing its goal of becoming an international-class drug-device integration platform.

“

Drug-device integration has been the core strategy of Guobio since its inception. With Puyen Biotechnology joining, the development capabilities for formulations and devices can be integrated within the same group. Regardless of the administration route, the group has the independent ability to complete the development of drug-device combination products.